Impact of Medicaid Unwinding on Medication Treatment for Opioid Use Disorder
A recent study links Medicaid unwinding to reduced initiation and continuation of medication treatment for opioid use disorder, emphasizing the importance of sustained access amidst policy changes.
Recent research by the RAND Corporation highlights significant shifts in medication treatment for opioid use disorder (OUD) following the end of pandemic-era Medicaid enrollment protections. The study reveals that as states resumed standard Medicaid procedures, over 25 million Americans experienced disenrollment, which correlates with notable declines in both initiation and continuation of treatment with medications like buprenorphine.
The investigation, which analyzed prescription data from all 50 states and the District of Columbia spanning from January 2021 to December 2023, found that the overall number of treatment episodes paid for by Medicaid decreased after unwinding began. States with the highest levels of disenrollment saw the largest reductions. Specifically, there was a 2.6% decrease in new Medicaid-paid treatment episodes during the six months following unwinding, with an even more significant 3.9% drop in states most affected by disenrollment.
While some individuals disenrolled from Medicaid may have accessed other payment methods for their medication, the data suggest that shifts in treatment episodes are not fully offset by alternative sources such as out-of-pocket payments or private insurance. The findings underscore a concerning trend: the ending of Medicaid continuous coverage is associated with decreased treatment engagement for individuals battling opioid addiction.
The study emphasizes the critical need to ensure sustained access to life-saving medications, especially as federal legislation predicts that up to 10 million Americans could lose Medicaid coverage by 2034. Medication-assisted treatment, particularly buprenorphine, remains the most effective approach for managing opioid use disorder, with Medicaid covering approximately 40% of these treatments.
Lead researcher Rachel K. Landis notes that the decline in treatment episodes correlates strongly with Medicaid disenrollment, especially in states experiencing the greatest unwinding. Experts warn that such disruptions could hinder progress in combating the opioid overdose crisis and highlight the importance of policy measures that maintain access to essential treatments.
[Source: https://medicalxpress.com/news/2025-09-medicaid-unwinding-medication-treatment-opioid.html]
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Study Finds No Survival Benefit of Concurrent Durvalumab with Chemoradiotherapy in Unresectable Stage III NSCLC
A groundbreaking phase III trial reveals that adding durvalumab concurrently with chemoradiotherapy does not improve overall survival in patients with unresectable stage III NSCLC, reaffirming the current standard of post-CRT consolidation therapy.
Primates Study Unveils Development of Ovarian Reserve, Advancing Women's Health Research
A groundbreaking study maps how the ovarian reserve develops in primates, offering new insights into women's reproductive health and potential approaches to treat infertility and hormonal disorders.
New Study Links PFAS Exposure in Firefighters to Gene Activity Alterations and Potential Health Risks
New research reveals that chemicals firefighters are exposed to may alter gene activity linked to cancer and neurological diseases, highlighting the importance of understanding PFAS health effects.
WHO Warns That Progress Against Non-Communicable Diseases is Slowing Down
The WHO warns that progress in combating non-communicable diseases is slowing, risking more lives worldwide. Urgent investments in cost-effective measures can save millions and generate significant economic benefits.